浅析门冬氨酸钾镁和胺碘酮治疗冠心病心衰的临床效果  

Analysis of the Clinical Effect of Potassium Magnesium Aspartate and Amiodarone in the Treatment of Coronary Heart Disease

作　　者：王海英[1] 

机构地区：[1]黑龙江省大庆市人民医院心内科,黑龙江大庆163000

出　　处：《中国卫生标准管理》2017年第26期84-85,共2页China Health Standard Management

摘　　要：目的研究分析冠心病心衰患者接受门冬氨酸钾镁与胺碘酮联合治疗的效果。方法 2014年3月—2015年6月对我院的36例冠心病心衰患者进行研究,作为对照组,使用常规治疗和胺碘酮治疗,选取2015年7月—2016年10月我院的冠心病心衰患者36例作为观察组,使用常规治疗、门冬氨酸钾镁和胺碘酮治疗,对两组的临床治疗效果进行比较分析。结果观察组的临床治疗有效率是91.7%,对照组的临床治疗有效率是77.8%,两组的治疗有效率对比差异存在统计学意义(P<0.05)。治疗前两组的射血分数差异不存在统计学意义(P>0.05),治疗后观察组上升幅度比对照组大(P<0.05)。结论冠心病心衰可以选择门冬氨酸钾镁与胺碘酮联合用药治疗,患者使用后心功能改善明显,安全性高。Objective To study the effect of combination of potassium magnesium aspartate and amiodarone in the treatment of heart failure patients with coronary heart disease.Methods 36 cases of coronary heart disease with heart failure in our hospital from March 2014 to June 2016 were selected as control group and treated with conventional treatment and amiodarone,36 cases of coronary heart disease with heart failure from July 2015 to October 2016 in our hospital were selected as the observation group and treated with conventional treatment,potassium magnesium aspartate and amiodarone,the clinical treatment effect of the two groups was comparative analyzed.Results The effective rate of clinical treatment in the observation group was 91.7%,and the effective rate in the control group was 77.8%.There was a statistically significant difference between the two groups in the treatment efficiency（P〈0.05）.Before treatment,there was no significant difference in ejection fraction between the two groups（P〈0.05）.After treatment,the increase of ejection fraction in the observation group was larger than that in the control group（P〈0.05）.Conclusion Potassium magnesium aspartate and amiodarone can be used in the treatment of coronary heart disease with heart failure,and the heart function is improved obviously,the safety is high.

关 键 词：门冬氨酸钾镁 胺碘酮 冠心病心衰 

分 类 号：R972[医药卫生—药品]